All companies

Rigid Metal & Glass

Shandong Pharmaceutical Glass

Broader sector Shanghai Stock Exchange: 600529
Headquarters
Zibo, CN
Segment
Rigid Metal & Glass
Stories held
5
Last story
31 Oct 2026

Shandong Pharmaceutical Glass is a Chinese maker of moulded glass containers for pharmaceutical packaging, including vials, ampoules and bottles, based in Shandong province. It is listed on the Shanghai Stock Exchange and became majority-owned by state group Sinopharm following a September 2026 share placement.

5 stories · 2026

Shandong Pharmaceutical Glass nine-month profit falls 4.1% on weak demand and rebate cut

Shandong Pharmaceutical Glass reported nine-month 2026 revenue of USD 488m (RMB 3.249bn), down 3.07% year on year. Net profit attributable to shareholders fell 4.09% to USD 78.2m (RMB 520m). The company cited weak domestic demand, stronger competition, higher inventories and the removal of export tax rebates on pharmaceutical glass from April 2026. Prior-period revenue was restated after a March 2026 correction moved a trading subsidiary's revenue recognition from gross to net, with no effect on profit or net assets. Sinopharm Group's proposed USD 481m (RMB 3.2bn) private placement to take control is still under Shanghai Stock Exchange review.

Why this mattersLost export rebates and weak domestic demand are eroding earnings at China's dominant pharma glass maker while Sinopharm's planned takeover still awaits exchange approval.

  • Nine-month 2026 revenue USD 488m (RMB 3.249bn), down 3.07% year on year
  • Nine-month net profit attributable to shareholders USD 78.2m (RMB 520m), down 4.09%
  • Q3 revenue USD 146m (RMB 969m), down 12.07%; Q3 net profit USD 22.4m (RMB 149m), down 12.79%
  • Export tax rebates on pharmaceutical glass removed from April 2026
  • 2023-2025 revenue restated after subsidiary Yiyuan Xinkang's trading revenue moved from gross to net recognition; no effect on profit
  • Sinopharm Group's proposed USD 481m (RMB 3.2bn) private placement for control remains under Shanghai Stock Exchange review
Shandong Pharmaceutical Glass Sinopharm Group counterparty
Relevant to you?

Sinopharm to take control of Shandong Pharmaceutical Glass via USD 484m share placement

Shandong Pharmaceutical Glass published a prospectus on 9 October 2026 for a private placement of new A-shares raising up to USD 483.86m (CNY 3,235.12m) from China National Pharmaceutical International and Shandong Yaoxin Health Industry. On completion, China National Pharmaceutical International becomes controlling shareholder, its parent Sinopharm actual controller and the State Council's state assets commission ultimate controller, replacing the Yiyuan county finance bureau. The final share count requires Shanghai Stock Exchange approval and China Securities Regulatory Commission registration.

Why this mattersControl of a listed maker of pharmaceutical bottles, stoppers and caps passes from a county finance bureau to Sinopharm, bringing part of a drug group's packaging supply in-house.

  • After the placement, China National Pharmaceutical International becomes controlling shareholder, with Sinopharm as actual controller.
  • The placement raises up to USD 483.86m (CNY 3,235.12m) in cash.
  • Up to 199,084,233 new shares will be issued, capped at 30% of the pre-issue share count.
  • At the cap, the two subscribers would hold 23.08% of the enlarged share capital.
  • Current controlling shareholder Shandong Luzhong Investment holds 19.50%; the Yiyuan county finance bureau is actual controller.
  • Shandong Pharmaceutical Glass (SSE: 600529) makes pharmaceutical bottles, stoppers and caps.
Shandong Pharmaceutical Glass China National Pharmaceutical Group counterparty
Relevant to you?

Lynoo Pharmaceutical Packaging nine-month profit falls 19% after Hong Kong listing filing

Shenzhen-listed Lynoo Pharmaceutical Packaging reported nine-month 2026 revenue up 38.78% to USD 150.5m (RMB 1.001bn). Net profit attributable to shareholders fell 19.03% to USD 6.19m (RMB 41.2m), and operating cash flow was an outflow of USD 7.8m (RMB 51.9m). Short-term borrowings rose 358.57% from end-2025. The company applied for a Hong Kong H-share listing on 28 September 2026. Proceeds are partly intended for ready-to-use packaging and pre-fillable syringes, and for a semiconductor glass substrate business that has no revenue or orders yet.

Why this mattersChina's ninth-largest pharma glass packager is raising capital abroad while profit and cash flow weaken, with proceeds partly funding a glass substrate line that has no orders yet.

  • Nine-month 2026 revenue USD 150.5m (RMB 1.001bn), up 38.78% year on year
  • Net profit attributable to parent USD 6.19m (RMB 41.2m), down 19.03%
  • Net operating cash outflow of USD 7.8m (RMB 51.9m) for the period
  • Short-term borrowings up 358.57% from end-2025
  • H-share listing application submitted to HKEX on 28 September 2026
  • Ranked ninth in China's pharmaceutical glass packaging market in 2025 with a 2.4% share
Gerresheimer mentioned Schott AG mentioned Shandong Pharmaceutical Glass mentioned Lynoo Pharmaceutical Packaging
Relevant to you?

China's Linuo Pharmaceutical Packaging files for Hong Kong listing

Shandong Linuo Pharmaceutical Packaging, listed on Shenzhen's ChiNext since November 2021, filed on 28 September 2026 for a main-board listing on the Hong Kong Stock Exchange, with China Merchants Securities International and Lego Financial Group as joint sponsors. The borosilicate glass maker ranks ninth in China's pharmaceutical glass packaging market and first in China, second globally, in daily-use heat-resistant glass. Proceeds are earmarked for industrialising semiconductor packaging glass substrates and RTU and PFS production.

Why this mattersA dual listing would give a leading Chinese borosilicate glass packaging player fresh capital to scale semiconductor glass substrates, a potential new growth line adjacent to pharma packaging.

  • Filed for Hong Kong main-board listing on 28 September 2026, already listed on Shenzhen ChiNext since 11 November 2021
  • Ranked 9th in China's pharmaceutical glass packaging market with 2.4% share by 2025 revenue, per Frost & Sullivan
  • Ranked 1st in China and 2nd globally in daily-use heat-resistant glass, with 9.5% domestic and 5.1% global market share
  • 2025 revenue was USD 146.4m (RMB 981.5m), down from USD 161.2m (RMB 1,080.8m) in 2024
  • 2025 net profit was USD 5.9m (RMB 39.7m), down from USD 9.9m (RMB 66.1m) in 2024
  • IPO proceeds earmarked for industrialising semiconductor packaging glass substrates and RTU and PFS production plus R&D
  • Adjusted net profit for H1 2026 rose 11.9% to USD 6.8m (RMB 45.837m), even as reported net profit fell 23.9% to USD 4.7m (RMB 31.157m).
Gerresheimer mentioned Schott AG mentioned Linuo Packaging Shandong Pharmaceutical Glass mentioned Chongqing Zhengchuan mentioned
Relevant to you?

Sinopharm takes control of Shandong Pharmaceutical Glass via USD 482.5m placement

Shandong Pharmaceutical Glass has filed with the Shanghai Stock Exchange to issue up to 199m new A-shares and raise up to USD 482.5m (CNY 3.235bn), with proceeds earmarked entirely for working capital. The placement hands control of the pharmaceutical glass maker to Sinopharm International, part of state-owned China National Pharmaceutical Group, replacing former controlling shareholder Luzhong Investment and the Yiyuan county finance bureau. The exchange accepted the filing on 17 September 2026; CSRC registration is still pending.

Why this mattersA central state conglomerate taking control of China's leading pharma glass maker could reshape supply terms and consolidation in the domestic pharmaceutical packaging chain.

  • Shandong Pharmaceutical Glass (600529.SH) plans to issue up to 199m new A-shares to raise up to USD 482.5m (CNY 3.235bn), entirely for working capital
  • Sinopharm International replaces Luzhong Investment and the Yiyuan county finance bureau as controlling shareholder, with the State Council's SASAC as ultimate controller
  • The Shanghai Stock Exchange accepted the placement filing on 17 September 2026; CSRC registration is still pending
  • The two cash subscribers are China International Medicine and Health Co and Shandong Yaoxin Health Industry Co
  • 2025 revenue fell 8.78% to USD 667m (CNY 4.474bn) and net profit fell 26.87% to USD 103m (CNY 690m), under centralised drug procurement pricing
  • Inventory rose to USD 259m (CNY 1.734bn) at end-June 2026 from USD 191m (CNY 1.279bn) at end-2024
  • The placement has cleared antitrust review and state-owned asset regulator approvals, pending Shanghai Stock Exchange and CSRC sign-off
  • Sinopharm entities would hold up to 23.08% after completion against 15% for outgoing controller Luzhong Investment, which has agreed not to seek control
  • Sinopharm would gain the right to nominate seven of the board's director seats
  • Completion requires the 20-day average share price before pricing to stay at or below RMB 31.25, failing which Sinopharm's subscription commitment and the control change lapse
Shandong Pharmaceutical Glass China National Pharmaceutical Group counterparty
Relevant to you?